A study to test different doses of BI 1831169 alone and in combination with ezabenlimab in people with different types of advanced cancer (solid tumors).
Phase 1
Recruiting
- Conditions
- solid tumorsTherapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2024-512504-19-00
- Lead Sponsor
- Boehringer Ingelheim International GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 95
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method